NCT07012317已完成不适用
A Randomized, Double-Blind Crossover Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications
Midwest Center for Metabolic and Cardiovascular Research2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年5月29日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Composite GI Symptom Score
研究概览
简要总结
The objective of this study is to assess self-reported gastrointestinal (GI) responses to three snack bars containing fiber/fiber blends vs. a control snack bar for 7 days each in adults using GLP-1 agonists.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female 25 to 64 years of age, inclusive. There will be approximately equal numbers of men and women.
- •Individual has a self-reported BMI of 18.5 to 39.9 kg/m2, inclusive.
- •Individual has been taking tirzepatide (≥10 mg weekly injection), semaglutide (≥2.0 mg weekly injection), or liraglutide (≥2.4 mg daily injection) for at least 4 weeks and plans to continue to take it throughout the duration of the study.
- •Individual has attained a high school diploma or a General Educational Development (GED) equivalent.
- •Individual has not participated in another research study within 30 days of the screening visit.
- •Individual is willing and able to undergo the scheduled study procedures.
- •Individual understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
排除标准
- •Individual has a clinically significant medical condition that, in the opinion of the Investigator, could interfere with the interpretation of the study results. Health conditions may include history or presence of clinically important GI, cardiac, renal, hepatic, endocrine, pulmonary, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Investigator. Clinically important GI conditions included but are not limited to: inflammatory bowel disease, irritable bowel syndrome, gastroparesis, clinically important lactose intolerance.
- •Individual habitually consumes >8 g fiber per 1000 kcal per day.
- •Individual had a recent (within two weeks of screening) episode of acute GI illness such as nausea, vomiting, or diarrhea.
- •Individual has a history of frequent diarrhea or constipation prior to beginning GLP-1 receptor agonist that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
- •Individual has a history of stomach or GI surgery (e.g., gastric bypass, cholecystectomy) that in the opinion of the Investigator, could interfere with evaluation of the study outcomes.
- •Individual uses medications (over-the counter or prescription) or dietary supplements known to influence gastrointestinal motility including laxatives, enemas, or suppositories; prokinetic drugs; anti-diarrheal agents, anti-spasmotics; fiber supplements; and prebiotic and probiotic supplements (Appendix 6). A 14-day washout phase prior to day 1 is allowed for participants taking any of these products.
- •Daily use of non-steroidal anti-inflammatory drugs (NSAIDs).
- •Individual has a history of cancer in the prior 2 years, except non-melanoma skin cancer or carcinoma in situ of the cervix.
- •Individual has a history of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).
- •History of any major trauma or major surgical event within 2 months of visit
- •Use of tobacco/nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit
- •Use of hemp/marijuana products within 12 months of visit
- •Occasional use (e.g., once or twice a month) within 12 months of visit 1 is allowed but requires at least a 14-day washout prior to day 1 and the participant must be willing to refrain from use during the study.
- •Individual is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
- •Individual has an allergy, sensitivity, or intolerance to any foods.
- •Individual has extreme dietary habits (e.g., vegan, Atkins diet, etc.).
- •Individual has signs or symptoms of an active infection of clinical significance or has taken antibiotics within 10 days prior to any visit (washout is permitted for re-scheduling of a visit).
- •Individual has a current or recent history (past 12 months of screening) or strong potential for illicit drug or excessive alcohol intake defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).
- •Individual has been exposed to any non-registered drug product within 30 days prior to screening.
- •Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.
研究组 & 干预措施
Experimental - Inulin
Experimental
干预措施: High Fiber Bar with Inulin (Other)
Experimental - Fiber Blend
Experimental
干预措施: High Fiber bar with Fiber Blend (Other)
Experimental - Resistant Starch Type 4
Experimental
干预措施: High Fiber Bar with Resistant Starch type 4 (Other)
Control - Low Fiber
Placebo Comparator
干预措施: Low Fiber Bar (Other)
结局指标
主要结局
Composite GI Symptom Score
时间窗: Measured on days 1-10, 25-34, 49-58, and 73-82 where day 1 is the virtual visit date and start of the 3-day baseline. Study product consumption begins on day 4, 28, 52, and 76 and continues for 7 days followed by a 14 day washout period.
Composite GI Symptom Score is from the GI Tolerability Questionnaire. The composite score will be calculated as the sum of the individual components (nausea, abdominal pain, bloating, intestinal rumbling, and flatulence). The ratings will be coded as: 1 = none/much less than usual, 2 = less than usual, 3 = about usual, 4 = more than usual, and 5 = much more than usual. There will be one composite score per day. Baseline will be defined as the average of the composite scores for the 3-day baseline period. The value for each intervention will be defined as the average of the composite scores for the 7-day intervention period.
次要结局
- The frequency of the individual component scores of the GI Tolerability Questionnaire (nausea, abdominal pain, bloating, intestinal rumbling, and flatulence) of 4 or higher (more than usual or much more than usual) during the 7-day intervention period.(Measured on days 1-10, 25-34, 49-58, and 73-82 where day 1 is the virtual visit date and start of the 3-day baseline. Study product consumption begins on day 4, 28, 52, and 76 and continues for 7 days followed by a 14 day washout period.)
- Change from baseline in the Bristol Stool Form Scale (BSFS)(Measured on days 1-10, 25-34, 49-58, and 73-82 where day 1 is the virtual visit date and start of the 3-day baseline. Study product consumption begins on day 4, 28, 52, and 76 and continues for 7 days followed by a 14 day washout period.)
- Change from baseline in the ratings of stool hardness, straining, discomfort, and incomplete evacuation.(Measured on days 1-10, 25-34, 49-58, and 73-82 where day 1 is the virtual visit date and start of the 3-day baseline. Study product consumption begins on day 4, 28, 52, and 76 and continues for 7 days followed by a 14 day washout period.)
- Change from baseline in the ratings for the individual component scores of the GIL Tolerability Questionnaire (nausea, abdominal pain, bloating, intestinal rumbling, and flatulence).(Measured on days 1-10, 25-34, 49-58, and 73-82 where day 1 is the virtual visit date and start of the 3-day baseline. Study product consumption begins on day 4, 28, 52, and 76 and continues for 7 days followed by a 14 day washout period.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female ParticipantsHealthyNCT04185051Janssen Research & Development, LLC76
已完成
3 期
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)OsteoarthritisNCT00092703Organon and Co6,000
已完成
不适用
Does Acupressure Affect Gastrointestinal Function, Pain and Anxiety?Pain, PostoperativeAnxietyGastrointestinal DysfunctionNCT04606485Kahramanmaras Sutcu Imam University53
已完成
不适用
Identification of Gluten Sensitivity in Irritable Bowel SyndromeNon-celiac Gluten SensitivityIrritable Bowel SyndromeNCT04017585University of Bari40
已完成
不适用
Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in ChocolateGastrointestinal ToleranceHealthy PopulationNCT06479330Mondelēz International, Inc.60